An oncology drug discovery and reprofiling company
Oncolodyne is a pre-clinical and clinical stage drug discovery company focused on reprofiling drugs for cancer therapy.
The drug reprofiling strategy (aka drug repurposing, indication expansion or reprofiling) discovers new uses for licensed drugs. Our aim is to develop and validate market blockbuster, safe and effective, small molecule cancer therapies and conduct clinical trials.
This drug reprofiling or repurposing strategy offers significant advantages over conventional drug development approach: Cost effective development, existing epidemiological and population level knowledge, known side effects and a fast track to clinical trials.
Oncolodyne utilizes novel approaches and cutting edge high-throughput technology to discover, validate and target novel mechanisms that are critical in carcinogenesis. Our platform offers a one stop facility from biological mechanisms to clinical translation, including clinical trial readiness and execution. We use informatics (curating and interrogating electronic health records using machine learning) with in vitro (electrophysiology, immunochemistry and confocal imaging based assays) and in vivo (transgenic models of cancer) techniques combined with target validation (human tissue based assay) to clinical trials in our drug discovery platform. This integrated reprofiling approach mitigate risks of clinical trial failure.
We are particularly focused upon reprofiling or repurposing membrane potential regulating compounds (MPRCs), small molecule drugs with known safety profile, as novel cancer therapies.
